Sign up Australia
Proactive Investors - Run By Investors For Investors

ResApp Health set to begin U.S. study of its app to diagnose respiratory diseases

An important step towards the commercialisation of ResAppDx in the U.S.
a smartphone
The app uses cough sounds to diagnose respiratory conditions

ResApp Health Ltd (ASX:RAP) has secured its third institutional review board (IRB) approval in the U.S. for a study that will evaluate the efficacy of the ResAppDx smartphone application.

The prospective double blind study is aimed at evaluating the efficacy of the ResAppDx app in diagnosing childhood respiratory diseases from cough sounds.

Planning to enrol up to 1,667 patients

Three hospital sites in the U.S. have now received IRB approval for the study – Massachusetts General Hospital, Texas Children’s Hospital and Cleveland Clinic Children’s.

The SMARTCOUGH-C-2 study plans to enrol up to 1,667 patients aged 29 days to 12 years of age who present to one of the three participating sites in the U.S. with signs or symptoms of respiratory disease.

ResApp’s co-primary endpoints from the study are positive and negative percent agreement with clinical diagnosis for various respiratory diseases.

These include pneumonia, lower respiratory tract disease, viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease and croup.

READ: Resapp Health embarking on new study to evaluate efficacy

The clinical diagnosis will be made by an independent, centralised clinical adjudication committee using all available clinical data, including radiology and microbiology.

Importantly, this represents another step towards the commercialisation of ResAppDx in the U.S.

The refined study includes major improvements over previous studies in the U.S., which is expected to deliver results that are more representative of ResAppDx’s performance.

View full RAP profile View Profile

ResApp Health Ltd Timeline

September 22 2017

Related Articles

cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
July 03 2018
The research and diagnostic company develops cancer-detecting blood tests

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use